GET A PIECE OF PHIZZLE
Data Integrity for the Pharmaceutical Industry
$141,858.05 Raised
REASONS TO INVEST
Phizzle’s software platform provides large-scale pharma companies means to digitize drug production data, which is integral to ensuring the safety and efficacy of cancer drugs and other FDA-regulated prescription medications.
Since 2005, Phizzle has been dedicated to creating innovative consumer and machine data solutions. To the best of our knowledge, ours is the only SaaS-based IoT software to remotely operate multiple scientific instrument brands and systems from a single, cloud-based user interface. Our novel approach has gained FDA-clearance and proof of concept validation through contract work with Fortune 75 pharma clients.
Phizzle is poised to partner with the world’s largest pharmaceutical companies by providing a solution that integrates with existing manufacturing systems and equipment. On a global scale, the installed base of scientific lab instruments exceeds 1M units across pharma, life sciences, clean manufacturing, food production, medical environments and office buildings. The market for these devices is growing, with particle counters, for example, projected at a 9% CAGR through 2027.*
*Information from Credible Markets, "Global Market Industry Value, Size, Share, Growth, Trends and Forecast, 2016-2027" for Analytical Balances, PH Meters, Particle Counters.
A Digital Solution For Unlocking Valuable Scientific Data in a Highly Regulated Environment
Phizzle’s cloud-native, microservices-based software platform offers world-leading pharmaceutical enterprises a solution to upgrade existing equipment, so they can produce life-saving medications with improved safety, compliance, and cost-efficiency.
Using our FDA-compliant system, drug companies are able to automate operations and enable optimized workflows, while also ensuring data integrity and minimizing the potential for human error. We believe ours is the first scalable platform of its kind targeting an entire ecosystem of devices waiting to be digitized across a landscape of laboratories worldwide.
The Problem & Our Solution
Modernizing Pharmaceutical Manufacturing Processes for Safety & Data Integrity
While the pharmaceutical industry is known for innovation, very little has changed in the world of drug production data. In order to be compliant with regulations and safety standards, laboratories rely on a variety of scientific instruments – including particle counters, balances, pH meters, and other equipment spanning decades of different makes and models – to manufacture pharmaceuticals.
For most companies, no central platform has previously existed to harmonize operations. As such, lab technicians still conduct a majority of testing manually, which results in a wide margin for human error. When mistakes happen, entire batches of product must be discarded and the recall process can total hundreds of millions of dollars, such as Pfizer’s infamous Bextra recall.
In order to avoid these kinds of costly errors, as well as ensure a safer and more streamlined production process, Phizzle has developed the digital architecture needed to capture this data holistically. Using our EDGMaker software platform, technicians are provided with all of the information from individual instruments on one digitized dashboard, which can be accessed and operated remotely.
*Testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.
(source)
*Testimonials may not be representative of the experience of other customers and is not a guarantee of future performance or success.
(source)
Phizzle has contracted with universities across the country to bring pharmaceutical device technology to the broader public - specifically air quality testing after the initial outbreak of COVID-19.
Scientific lab instruments are some of the best tools in the world for diagnosis and measurement. Phizzle works with institutions like the University of Arizona to use them for quantifying and improving air quality on campuses.
For example, our particle counter testing at University of Arizona showed consistent and predictable "bad air" spikes during highly-trafficked hours at the largest student center. Data also indicated consistently bad air in the most trafficked reception area because the floor trash cans were placed next to the front desk where students waited. They were rarely emptied throughout the day and an easy change to make for the university.
Arizona changed the location of their trash and shifted foot traffic during COVID-19 to improve air quality and help keep students safe. Phizzle provided the device know-how and platform to implement immediate and actionable changes during this process.
The Market & Our Traction
Achieving Major Milestones on Our Way to Serving the Global Pharma Industry
For the past few years, Phizzle has been making significant strides to establish the EDGMaker software stack as an industry-innovating technology. Our platform is unique to the market, in that it has already secured FDA approval for our use case and designation for virtualizing scientific lab instruments. With this clearance in place, the company has gained a competitive edge and accomplished proof of concept by partnering with its first Fortune 75 pharmaceutical manufacturer.
Through our work we’ve been able to successfully digitize more than 40K samples from facilities producing one of the world’s best-selling cancer treatment drugs, and are on pace to reach 100K by the end of this year.
(source)
We’ve also effectively doubled our total addressable market by adding three new scientific lab instruments to our portfolio, and been recognized by Forbes.com, CRN, and the IoT Community.
Why Invest
Our Vision is Validated through Fortune Company Partnerships & Greenlit by the FDA
Although Phizzle started as a small technology company, achieving FDA-compliant status and signing with a Fortune 75 pharma customer are a testament to the technology we've developed and our in-market advantage.
As we surpass our goal of 100K digitized samples and continue to grow our pipeline of potential customers to include other large-scale pharmaceutical customers, support from funding will allow us to expand our resources and serve the industry on a global scale. Help us continue on our trajectory to success by investing today!
ABOUT
HEADQUARTERS
943 Howard Street
San Francisco, CA 94103
WEBSITE
View Site
Phizzle is a market leader in automating and digitizing scientific lab instruments used in pharma and other clean manufacturing environments. The vast majority of these instruments are not connected to a cloud based solution to harmonize or digitize their data. Phizzle is a first-mover in this market with a patented IoT solution that can remotely operate multiple types and vendors of lab instruments from the cloud. Phizzle has a recurring revenue contract with a Fortune 75 company and is FDA-compliant in its use case, which we believe is the first of its kind. The company is seeking funding to scale its operations and accelerate its current pipeline.
TEAM
Ben Davis III
Chief Executive Officer, Board Member, Director
William Valtos
Director
Professional Expertise: A former investment banking CEO, Mr. Valtos has a deep network and extensive deal experience in Silicon Valley, Southeast Asia, and Japan. He has managed a number of businesses in different geographies and has cross-border experience in mergers and acquisition, capital markets strategy, venture capital, private equity, and strategic finance. Mr. Valtos co-founded and led a Top-Quartile venture capital firm, tracked. He is well-regarded for building strong corporate cultures and committed teams, organizational change, and corporate governance.
James Whims
Director
Kari Baker
VP Customer Success & Operations
Thomas Toy
Director
Stephen Peary
Chief Financial Officer and General Counsel
Ryan Brady
Chief Technical Officer
Ron Ricci
Chair of Board
Mark Krentzman
Director
Mr. Krentzman has a strong track record as an entrepreneur in working with software, medical technology, internet and telecommunications businesses, both in connection with fundraising and identifying significant opportunities for investment and growth in these fields, as well as helping in the turnaround of under-performing companies and creating significant value for shareholders.
Mr. Krentzman received a MBA from the Harvard University Graduate School of Business with an emphasis on manufacturing and marketing, and a BS in Finance, Magna Cum Laude, from Northeastern University School of Business. He currently serves as an Emeritus Corporator of Northeastern University and served as Co-Chair of his HBS Alumni Class. He also serves as a Trustee Emeritus of the Norman Rockwell Museum in Stockbridge, MA. Mr. Krentzman Is an Owner of Jones & Vining.
Edwin Lau
Director and Acting President
Michael Patrick
Chief Innovation Officer
Lena Wu
Industry Advisor
Cecilie Carter
Senior Director
TERMS
Phizzle
Overview
PRICE PER SHARE
$0.40
DEADLINE
Mar 16, 2023
VALUATION
$78.29M
FUNDING GOAL
$10k - $5M
Breakdown
MIN INVESTMENT
$200
MAX INVESTMENT
$5,000,000
MIN NUMBER OF SHARES OFFERED
25,000
MAX NUMBER OF SHARES OFFERED
12,500,000
OFFERING TYPE
Equity
ASSET TYPE
Common Stock
SHARES OFFERED
Common Stock
Maximum Number of Shares Offered subject to adjustment for bonus shares
Voting Rights of Securities Sold in this Offering
Voting Proxy. Each Subscriber shall appoint the Chief Executive Officer of the Company (the “CEO”), Chairman of the Board of Directors, or his or her successor, as the Subscriber’s true and lawful proxy and attorney, with the power to act alone and with full power of substitution, to, consistent with this instrument and on behalf of the Subscriber, (i) vote all Securities, (ii) give and receive notices and communications, (iii) execute any instrument or document that the CEO determines is necessary or appropriate in the exercise of its authority under this instrument, and (iv) take all actions necessary or appropriate in the judgment of the CEO for the accomplishment of the foregoing. The proxy and power granted by the Subscriber pursuant to this Section are coupled with an interest. Such proxy and power will be irrevocable. The proxy and power, so long as the Subscriber is an individual, will survive the death, incompetency and disability of the Subscriber and, so long as the Subscriber is an entity, will survive the merger or reorganization of the Subscriber or any other entity holding the Securities. However, the Proxy will terminate upon the closing of a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933 covering the offer and sale of Common Stock or the effectiveness of a registration statement under the Securities Exchange Act of 1934 covering the Common Stock.
*Maximum number of shares offered subject to adjustment for bonus shares. See Bonus info below.
Investment Incentives and Bonuses*
Time Based Bonus
Friends and Family Early Birds
Invest $200 within the first 48 hours and receive 20% bonus shares.
Super Early Bird Bonus
Invest $200 within the first week and receive 15% bonus shares.
Early Bird Bonus
Invest $200 within the first month and receive 10% bonus shares.
Amount-Based:
$500+ | Tier 1
Invest $500+ and receive 5% bonus shares.
$1,000+ | Tier 2
Invest $1,000+ and receive 10% bonus shares.
$5,000+ | Tier 3
Invest $5,000+ and receive 15% bonus shares.
$10,000+ | Tier 4
Invest $10,000+ and receive 20% bonus shares.
$20,000+ | Tier 5
Invest $20,000+ and receive 20% bonus shares and an invite to a webinar with the CEO
Loyalty Bonus:
As you are an existing Stockholder / Noteholder/ TTW Email recipient in Phizzle, receive 10% Additional Bonus Shares.
*In order to receive perks from an investment, one must submit a single investment in the same offering that meets the minimum perk requirement. Bonus shares from perks will not be granted if an investor submits multiple investments that, when combined, meet the perk requirement. All perks occur when the offering is completed.
The 10% StartEngine Owners' Bonus
Phizzle, Inc will offer 10% additional bonus shares for all investments that are committed by investors that are eligible for the StartEngine Crowdfunding Inc. OWNer's bonus.
This means eligible StartEngine shareholders will receive a 10% bonus for any shares they purchase in this offering. For example, if you buy 100 shares of Common Stock at $0.40/ share, you will receive 110 shares of Common Stock, meaning you'll own 110 shares for $40. Fractional shares will not be distributed and share bonuses will be determined by rounding down to the nearest whole share.
This 10% Bonus is only valid during the investor's eligibility period. Investors eligible for this bonus will also have priority if they are on a waitlist to invest and the company surpasses its maximum funding goal. They will have the first opportunity to invest should room in the offering become available if prior investments are canceled or fail.
Investors will receive the highest single bonus they are eligible for among the bonuses based on the amount invested and the time of offering elapsed (if any). Eligible investors will also receive the Owner’s Bonus and an audience-based bonus of 10% for Phizzle Existing Stockholders/Noteholders/TTW Email Recipients, in addition to the aforementioned bonus.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments. Salary payments made to one’s self, a friend or relative. Any expense labeled “Travel and Entertainment”.
PRESS
ALL UPDATES
Stack Owner's Bonus & Rewards!
Members get an extra 10% shares in addition to rewards below!
REWARDS
JOIN THE DISCUSSION
0/2500
Elias Phew
9 months ago
Awesome mission, and congratulations on your progress so far! Do you have a sense of contract size per client as you scale, and how many contracts you'll need to break-even? And perhaps how many clients you're looking to onboard over the next 2-3 years?
1
0
Yehoshua Starrett
9 months ago
Thanks for your response, but you haven't stated what is the value of each instrument for your top/bottom lines.
1
0
Yehoshua Starrett
9 months ago
Maybe it's discussed in some conversation here, but I did not see discussed in anywhere in the presentation how big is the total market in $$ that could use your product and what are your realistic expectations of market capture %? Or in other words, what are your realistic expectations of revenue say 5 and 10 years from now and what do you expect your profit margin to be?
1
0
Mark Krentzman
10 months ago
How many Scientific Instruments does Phizzle's Edge Software work on today?
1
0
Alfred Carter
10 months ago
How do you go-to-market? Do you sell direct? Through channel partners?
1
0
Ronald Ricci
10 months ago
I’m a Phizzle investor, board member and acting CMO at the company. I spent 20 years with Cisco, including a decade in the C-suite and a decade in a global sales role. Cisco sold to the similar B2B buyers as we do at Phizzle. I’ve been in customer meetings with Phizzle, and we are working directly with senior decision-makers in IT. Our solution is in production and has already scaled to additional facilities for the customer. Our sales pipeline has multiple global pharma companies considering proof-of-value pilots. We’re excited to have the support of the StartEngine community to help us continue on our winning streak and scale faster than we could on our own. I hope you will considering watching my Investor Video on Phizzle’s StartEngine landing page!
1
0
Edwin Lau
10 months ago
I have been involved with Phizzle for a number of years, first as an investor and then as an acting operating executive. The company is succeeding as an enterprise software company within Pharma manufacturing, an extremely daunting task for any software company let alone a startup company given the rigor needed to achieve Good Manufacturing Practices (GMP) standards. In my opinion, the team is one of the best I've worked with in my 30+ years in technology and I am excited to be a part of the company as an investor for what lies ahead for Phizzle.
1
0
Christopher Ivey
10 months ago
Where is the cap table.
What stock classes exist and what are the terms that differentiate them from the common.
Is there any form of debt (including convertible notes) that exists.
Where is your pro forma and any financial information.
What are the employment/compensation terms of the founders/c-suite.
Why is a company with 25M in VC funding doing a relatively small reg CF raise. Going from professional to retail investors at this stage seems questionable.
What are the commercial terms of your Fortune 75 Client.
1
0
Logan Carter
10 months ago
Can you tell us more about your customer and other prospects in your pipeline?
1
0
HOW INVESTING WORKS
Cancel anytime before 48 hours before a rolling close or the offering end date.
WHY STARTENGINE?
REWARDS
We want you to succeed and get the most out of your money by offering rewards and memberships!
SECURE
Your info is your info. We take pride in keeping it that way!
DIVERSE INVESTMENTS
Invest in over 200 start-ups and collectibles!
With Regulation A+, a non-accredited investor can only invest a maximum of 10% of their annual income or 10% of their net worth per year, whichever is greater. There are no restrictions for accredited investors.
With Regulation Crowdfunding, non-accredited investors with an annual income or net worth less than $124,000, are limited to invest a maximum of 5% of the greater of those two amounts. For those with an annual income and net worth greater than $124,000, he/she is limited to investing 10% of the greater of the two amounts.
At the close of an offering, all investors whose funds have “cleared” by this time will be included in the disbursement. At this time, each investor will receive an email from StartEngine with their Countersigned Subscription Agreement, which will serve as their proof of purchase moving forward.
Please keep in mind that a company can conduct a series of “closes” or withdrawals of funds throughout the duration of the campaign. If you are included in that withdrawal period, you will be emailed your countersigned subscription agreement and proof of purchase immediately following that withdrawal.
StartEngine assists companies in raising capital, and once the offering is closed, we are no longer involved with whether the company chooses to list shares on a secondary market, or what occurs thereafter. Therefore, StartEngine has no control or insight into your investment after the close of the live offering. In addition, we are not permitted to provide financial advice. You may want to contact a financial professional to discuss possible investment outcomes.
For Regulation Crowdfunding, investors are able to cancel their investment at any point throughout the campaign up until 48 hours before the closing of the offering. Note: If the company does a rolling close, they will post an update to their current investors, giving them the opportunity to cancel during this timeframe. If you do not cancel within this 5-day timeframe, your funds will be invested in the company, and you will no longer be able to cancel the investment. If your funds show as ‘Invested’ on your account dashboard, your investment can no longer be canceled.
For Regulation A+, StartEngine allows for a four-hour cancelation period. Once the four-hour window has passed, it is up to each company to set their own cancelation policy. You may find the company’s cancelation policy in the company’s offering circular.
Once your investment is canceled, there is a 10-day clearing period (from the date your investment was submitted). After your funds have cleared the bank, you will receive your refund within 10 business days.
Refunds that are made through ACH payments can take up to 10 business days to clear. Unfortunately, we are at the mercy of the bank, but we will do everything we can to get you your refund as soon as possible. However, every investment needs to go through the clearing process in order to get sent back to the account associated with the investment.
Both Title III (Regulation Crowdfunding) and Title IV (Reg A+) help entrepreneurs crowdfund capital investments from unaccredited and accredited investors. The differences between these regulations are related to the investor limitations, the differing amounts of money companies are permitted to raise, and differing disclosure and filing requirements. To learn more about Regulation Crowdfunding, click here, and for Regulation A+, click here.
Archibald Mcgeoch
9 months ago
1
0